# Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies

> **NCT03637764** · PHASE1,PHASE2 · TERMINATED · sponsor: **Sanofi** · enrollment: 107 (actual)

## Conditions studied

- Neoplasm

## Interventions

- **DRUG:** Isatuximab SAR650984
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT03637764
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-08-06
- **Primary completion:** 2022-05-11
- **Final completion:** 2022-05-11
- **Target enrollment:** 107 (ACTUAL)
- **Why stopped:** Study was stopped after interim analysis for 4 cohorts (HCC, SCCHN, EOC, and GBM) indicated that the results did not fulfill the preplanned interim analysis criteria to move to Phase 2 stage 2 in all 4 cohorts.
- **Last updated:** 2023-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03637764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03637764, "Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03637764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*